A Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor , WX-554 , in patients with advanced solid tumours

a. Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. b. Northern Centre for Cancer Care, Newcastle Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK. c. Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK d. UCB, 216 Bath Road, Slough, SL1 4EN, UK. e. WILEX AG, Grillparzerstr. 18, 81675 Munich, Germany. f. Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK and Northern Ireland Cancer Center, Belfast City Hospital, Belfast, UK g. Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, G12 OYN, UK. h. St. James's Institute of Oncology, Beckett Street, Leeds, LS9 7TF, UK. i. The Christie NHS Foundation Trust / The University of Manchester, Manchester, M20 4BX, UK.